[ad_1]
Evolva (SIX: EVE) today announced the receipt of a letter from the US Environmental Protection Agency (EPA) shortly before scheduled regulatory registration.
As part of its in-depth review of Evolvas' application to register Nootkatone as a product for manufacturing, the Agency identified a study for which it was unable to complete its review and requested information. complementary.
Evolva is interacting closely with EPA to resolve the identified problem and determine next steps, which will include an extension of the regulatory deadline. Evolva will inform its stakeholders as soon as it gains visibility.
Evolva remains fully committed to the project and is confident that Nootkatone will be registered as an active ingredient against ticks and mosquitoes.
About nootkatone
DO YOU WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe for free to the newsletter Global Banking & Finance Review Access exclusive reports to save time and money
By using this form, you accept the storage and processing of your data through this site. We will not spam, rent or sell your information.
All emails include an unsubscribe link. You can unsubscribe anytime. See our privacy policy.
Nootkatone is an ingredient present in trace amounts in the bark of the Yellow Cedar of Alaska (also called Nootka Cypress) and in the grapefruit skin. Nootkatone has a long history as an approved flavor and fragrance. It can also be produced on an industrial scale from brewing via yeast fermentation. Nootkatone has been tested on various pungent arthropods, including ticks responsible for the spread of Lyme disease and spreading mosquitoes such as Zika, Chikungunya, dengue and West Nile viruses.
About the collaboration between Evolvas, CDC and BARDA
This project was funded by federal funds from Centers for Disease Control and Prevention (CDC) and managed by the Office of the Assistant Secretary for Preparedness and Response (ASPR), Authority for Advanced Research and Development in the biomedical field (BARDA), under HHSO100201700015C.
About Lyme Disease and Zika Virus
Lyme disease is caused by bacteria Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks Ixodes scapularis and Ixodes pacificus). The Zika virus is transmitted mainly by the bite of an infected Aedes mosquito species (Ae. aegypti and Ae. albopictus). There is no vaccine or medicine for Zika; The best protection is to avoid mosquito bites.
About tick-borne and mosquito-borne diseases in the United States
Last year, the CDC released a report indicating that mosquito, tick and flea-related diseases had tripled from 2004 to 2016. The report warned that better options are needed in the fight against malaria. these disease vectors. "Generalized and difficult to control diseases, such as mosquitoes, ticks and flea bites, are the leading causes of disease and death worldwide. The increasing number of these diseases and their spread pose a growing risk in the United States. The report revealed that the country needed to be better prepared to deal with this threat to public health.
About Evolva
Evolva solves the problems of the supply chain of nature through a blend of biotechnology and fermentation of the 21st century. We develop, manufacture and sell ingredients that bring significant benefits to the health, well-being and nutrition of people in their daily lives, but whose supply chain issues have limited their use to the point of use. 39, now. Our key ingredients are stevia, nootkatone and resveratrol. To make our world sustainable, nature and technology must be combined and our goal is to play a (small) role in the realization of this transformation. For more information, see https://www.evolva.com.
This press release contains specific forward-looking statements, for example: statements including terms such as believe, badume, expect or similar expressions. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, development or performance of the Company to be materially different from those explicitly or implicitly badumed in such statements. statements. There can be no badurance that Nootkatone will be registered as a product for manufacturing purposes. There is no guarantee that Nootkatone as a PM (for formulation in end-use products) will have commercial success in the future. In particular, the uncertainties inherent in research and development, including unexpected test results and / or any other unexpected gaps that the EPA might identify during its ongoing review of the application, could, among other things, affect the direction with respect to Nootkatone. Given these uncertainties, readers should not place undue reliance on forward-looking statements. The Company badumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
Oliver Walker, CEO
[email protected]
+
41 61 485 2034
Paul Verbraeken, IR
[email protected]
+
41 61 485 2035
Stephan Herrera, USA
[email protected]
+
1,415,794,4005
Source link
